Cytomegalovirus infection secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]
Overview
Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.
Secondary Prevention
- Secondary prevention of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.[1][2][3]
References
- ↑ Santos CA (2016). “Cytomegalovirus and Other β-Herpesviruses”. Semin Nephrol. 36 (5): 351–361. doi:10.1016/j.semnephrol.2016.05.012. PMID 27772620.
- ↑ Potena L, Solidoro P, Patrucco F, Borgese L (2016). “Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update”. Expert Opin Pharmacother. 17 (12): 1611–22. doi:10.1080/14656566.2016.1199684. PMID 27340928.
- ↑ Kotton, C. N. (2013). “CMV: Prevention, Diagnosis and Therapy”. American Journal of Transplantation. 13 (s3): 24–40. doi:10.1111/ajt.12006. ISSN 1600-6135.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH